What Can We Expect from the ISSUE 3 Trial?

DOI 20 References
  • Sutton Richard
    Clinical Cardiology and Consultant Cardiologist, Imperial College and Imperial College Healthcare NHS Trust St Mary’s Hospital
  • Brignole Michele
    Head of Department of Cardiology, Ospedali del Tigullio, Servizio Sanitario Nazionale

Search this article

Description

The ISSUE 3 Trial is designed to demonstrate which patients with vasovagal syncope over the age of 40 years will benefit from pacing dual chamber with the rate drop response. The trial has completed its recruitment of 521 patients and 78 have now been randomized in Phase 2, which is the Pacing ON versus Pacing OFF comparison. During this Phase the end-points are recurrence of syncope or two years of follow-up without recurrence. It has been calculated that 27 early end-points will be sufficient to determine a significant difference between the groups. The background, details and design of the trial are explained. Some early findings are presented. Definitive results are expected by the end of 2011.

Journal

References(20)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top